Twist Bioscience Corp (TWST)

Twist Bioscience is a biotechnology company that manufactures and sells synthetic DNA — engineered DNA sequences made to customer specifications or as standardized reagents used in research, drug discovery, and manufacturing. The company produces two core product lines: custom and tools DNA (made-to-order sequences for researchers and pharmaceutical companies) and synthetic biology offerings (reagents and platforms for cell engineering and strain development). It also operates a COVID-19 diagnostics business that emerged during the pandemic. Twist’s business model is software-like in structure (digital designs, manufactured products) but capital-intensive in execution, requiring specialized equipment and manufacturing facilities. The company is not yet profitable at the operating level and depends on continued customer spending in the biotech and pharmaceutical sectors.

Custom DNA synthesis at scale

Twist’s foundational business is the design and synthesis of custom DNA sequences. Researchers and pharmaceutical companies need synthetic DNA for molecular cloning, gene editing, creating expression systems, and validating genetic hypotheses. Historically, this was a slow, expensive process. Twist developed manufacturing technology that could produce custom DNA faster and cheaper than legacy suppliers, and it scaled that capability to serve thousands of customers worldwide.

The company takes digital specifications (a text file describing a DNA sequence, length, and specifications) and translates them through automated manufacturing systems into physical DNA that arrives at the customer’s lab. The digital-to-physical translation is where Twist’s proprietary advantage lies — its manufacturing platform uses chip-based synthesis and optical technologies to parallelize the process, bringing costs down and timelines from weeks to days. This speed and cost advantage relative to older competitors like Genemart (acquired by Thermo Fisher) made Twist the market leader in custom DNA by the early 2020s.

The business is recurring: as a researcher generates new hypotheses or validates compounds, they order more sequences. As pharmaceutical companies screen drug candidates or develop manufacturing processes, they require high volumes of custom DNA. The installed base of customers creates a natural moat — switching costs are low, but customer habits are sticky.

Tools and reagents: the consumable play

Beyond custom synthesis, Twist sells kits and reagents that researchers use in DNA cloning, amplification, and engineering workflows. These tools are smaller purchases than custom synthesis orders but more frequent — a research lab might buy a kit every few weeks. The business model is classic consumables: sell tools at a small margin per unit, but scale the volume across thousands of labs worldwide. Tools and reagents generate lower revenue per customer than custom synthesis but higher gross margins and better retention.

This segment competes with established life-sciences vendors like Thermo Fisher, Bio-Rad, and others, and Twist is a smaller player. However, Twist’s advantage is that its tools integrate with its custom DNA offering — customers who buy custom sequences naturally use Twist kits in downstream workflows, creating cross-selling momentum.

Synthetic biology and strain engineering

Twist’s higher-margin, long-term opportunity is in synthetic biology — the engineering of cells and organisms to produce desired products (drugs, enzymes, chemicals). The company offers platforms and reagents that help biotech and pharma customers design and test cell lines for bioproduction. A company developing an enzyme to break down plastic, or producing therapeutic proteins in engineered yeast, would use Twist’s design tools and DNA synthesis to build, test, and iterate candidate strains.

This segment was early and nascent for years, but accelerated in the late 2010s and 2020s as cell and gene therapies, biomanufacturing, and protein engineering became mainstream priorities. Twist’s ability to synthesize large, complex DNA constructs and integrate them into cell-engineering workflows positioned the company well. However, this segment remains a small percentage of total revenue and is highly competitive — larger players like Ginkgo Bioworks (which competes in strain engineering) have raised substantial capital and are building similar capabilities.

COVID-19 diagnostics: a temporary windfall and structural decline

During the COVID-19 pandemic, Twist developed and commercialized a COVID-19 diagnostic test that generated significant revenue in 2020 and 2021. The diagnostics business was a source of cash and brand visibility. However, demand for COVID tests has normalized to a fraction of the pandemic peak, and Twist’s diagnostics revenue has declined sharply. The company is no longer reporting this as a primary strategic focus, treating it as legacy revenue that will continue to decline. This illustrates a risk for biotech companies that depend on pandemic-driven or crisis-driven demand — when the crisis ends, so does the revenue.

Customer concentration and spending cycles

Twist depends on a concentrated customer base of pharmaceutical companies, large biotech firms, contract research organizations, and academic researchers. A handful of customers likely account for a material percentage of revenue. Pharmaceutical and biotech customer spending is tied to R&D budgets, which fluctuate with industry dynamics, regulatory environments, and capital availability. A broad pullback in biotech spending — say, during a market downturn or a reduction in venture capital funding — would hit Twist’s top line.

Additionally, large pharmaceutical customers are price-sensitive. If a competitor matches Twist’s capabilities at a lower cost, or if a customer develops in-house manufacturing capabilities, Twist loses that business. The switching cost for customers is low — DNA is DNA, and if another supplier can deliver comparable quality and speed at a better price, customers will switch.

Cash burn and the path to profitability

Twist has historically operated at a loss or thin margin because it reinvests heavily in R&D, manufacturing scale-up, and market development. The company burns cash in pursuit of scaling volume and improving unit economics. At some point profitability requires either revenue to accelerate enough to cover fixed costs, or the company to reduce spending and focus on current markets. The company’s ability to raise capital in public markets and through debt has allowed it to pursue growth, but that option is contingent on investor appetite for biotech companies without clear near-term profitability. A market environment where biotech funding dries up would pressure Twist’s ability to continue burning cash while building the business.

Competitive and regulatory risks

Twist operates in a space with established competitors (Thermo Fisher, Bio-Rad, IDT/Integrated DNA Technologies), as well as smaller specialized players. Larger competitors have more capital, broader product portfolios, and established customer relationships. They can integrate DNA synthesis into broader life-sciences platforms and cross-sell aggressively. Twist must maintain its technological lead and cost advantage to compete.

On the regulatory side, if DNA synthesis becomes restricted (due to biosecurity concerns or export controls), the business could be disrupted. Governments and industry bodies have debated controls on DNA synthesis to prevent malicious use of genetic engineering. Any broad restrictions would affect Twist’s addressable market, though it is unlikely that legitimate commercial and research uses would be prohibited outright.

The core risk to the business model

Twist’s viability depends on three things holding true: that synthetic DNA synthesis remains a critical tool in biotech and pharma, that customers continue to choose outsourced synthesis over building in-house capabilities, and that Twist can scale volume and improve unit economics faster than competitors drive prices down. If any one of those breaks, the company’s growth and profitability suffer. A scenario in which large pharmaceutical companies or well-funded biotech firms develop or acquire in-house DNA synthesis capabilities, thereby reducing addressable market for outsourced synthesis, would compress Twist’s market and its margins.

Additionally, if synthetic biology and cell engineering become saturated with competitors and Twist cannot defend its market position, revenue growth stalls and the company’s losses become harder to justify to investors. A prolonged biotech spending slowdown would also pressure the company’s ability to sustain growth and reach profitability.

Researching Twist as an investor

Start with the 10-K filing (SEC CIK 0001581280) to understand revenue breakdowns by segment, gross margins by business line, and cash burn. The company’s balance sheet — particularly cash levels and debt terms — is critical because profitability is not yet achieved and will depend on raising capital or reaching cash flow breakeven.

Key metrics: revenue growth rate (whether accelerating or decelerating), gross margin trends (reflecting pricing and manufacturing efficiency), customer concentration (is revenue diversifying or concentrated in a few large customers?), and cash burn rate (how long can the company operate at current burn without raising more capital?). Compare Twist’s gross margins and growth profile to peers in synthetic biology and research tools to understand competitive position.

The investment case for Twist is based on belief that synthetic DNA synthesis becomes a larger category in biotech, that Twist maintains competitive advantage, and that the company can achieve profitability at meaningful scale. This is not investment advice — only a map of where the business’s revenue comes from and what could threaten it.